News

Specifically, the research examined the co-administration of MCT-465, a toll-like receptor (TLR) agonist and IgNP, the company's antigen presenting immunoglobulin therapeutic. It found that the combination therapy not

The agreement includes annual license fees and milestone payments which could total approximately $38 million paid to Neuralstem for each licensed product. The license covers a library of

Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently in phase III development. The companies plan to file for US regulatory approval of saxagliptin during the first half of

Organon plans to continue research and development aiming at clinical application of the Academic Medical Center (AMC) for treatment of rheumatoid arthritis and possible other diseases. Under the

The researchers reported that rats receiving the diabetes drug Actos before, during and after radiation treatments did not experience cognitive impairment. The scientists compared whether treatment with Actos

The neuroscience partnership announced in April 2004 between Solvay and Wyeth has already resulted in a new drug application for bifeprunox for the treatment of patients with schizophrenia.

Elaprase replaces the enzyme, iduronate-2-sulfatase (I2S), that people with this disorder fail to produce in sufficient quantities. This lack of enzyme interferes with the body’s ability to break

The primary endpoint of the trial was statistical non-inferiority versus combination therapy. Ceftobiprole demonstrated high cure rates in patients with skin infections including diabetic patients with foot infections.

According to Roche the expansion of the product label provides benefits for the patients as they will no longer have the burden of three injections per week. Anemia